OVID Ovid Therapeutics Inc.
Healthcare$2.47+1.23%ClosedMarket Cap: $325.8M
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
0.92
P/S
45.74
EV/EBITDA
-4.90
DCF Value
$-0.83
FCF Yield
-12.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.5%
Operating Margin
-670.2%
Net Margin
-339.3%
ROE
-22.5%
ROA
-10.7%
ROIC
-22.6%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-17.8M | $-17.0M | $— | — |
| Q4 null | $718.0K | 100.0% | $-12.3M | $9.7M | $— | — |
| FY null | $7.3M | 95.9% | $-42.4M | $-17.4M | $— | — |
| Q3 null | $132.0K | 100.0% | $-12.5M | $-12.2M | $— | — |
| Q2 null | $6.3M | 100.0% | $-5.1M | $-4.7M | $— | — |
| Q1 null | $130.0K | 100.0% | $-12.6M | $-10.2M | $— | — |
| Q4 null | $76.0K | 100.0% | $-10.7M | $-9.3M | $— | — |
| FY null | $566.0K | 100.0% | $-61.9M | $-26.4M | $— | — |
| Q3 null | $173.0K | 100.0% | $-13.2M | $-14.0M | $— | — |
| Q2 null | $169.0K | 100.0% | $-20.5M | $8.5M | $— | — |
| Q1 null | $148.0K | 100.0% | $-17.4M | $-11.7M | $— | — |
| Q4 2023 | $142.0K | 100.0% | $-18.2M | $-15.3M | $-0.22 | — |